tiprankstipranks
Editas Medicine Inc (CH:8EM)
:8EM
Switzerland Market
8EM
Editas Medicine
RESEARCH TOOLSreports

Editas Medicine (8EM) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

8EM Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
6 Buy
3 Hold
2 Sell
Based on 11 analysts giving stock ratings to
Editas
Medicine
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

8EM Stock 12 Month Forecast

Average Price Target

CHF5.03
Based on 11 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is CHF5.03 with a high forecast of CHF11.84 and a low forecast of CHF3.16. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF11.84Average Price TargetCHF5.03Lowest Price TargetCHF3.16
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on CH:8EM
Jonathan Miller
Evercore ISI
Evercore ISI
CHF11.84
Buy
―
Reiterated
05/27/26
Editas Medicine preclinical data 'looks highly supportive,' says Evercore ISIEditas Medicine preclinical data 'looks highly supportive,' says Evercore ISI
H.C. Wainwright Analyst forecast on CH:8EM
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF3.95
Buy
―
Reiterated
05/26/26
Analyst Maintains Buy on Editas Medicine, Reiterates $5 Price Target on EDIT-401 Progress and Strong Cash Runway
JonesTrading Analyst forecast on CH:8EM
Boris Peaker
JonesTrading
JonesTrading
CHF10.26→CHF6.31
Buy
―
Reiterated
05/14/26
JonesTrading Keeps Their Buy Rating on Editas Medicine (EDIT)
Bank of America Securities Analyst forecast on CH:8EM
Alec Stranahan
Bank of America Securities
Bank of America Securities
―
Sell
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (NYSE: BKD), Tempus AI, Inc. Class A (NASDAQ: TEM) and Editas Medicine (NASDAQ: EDIT)
TD Cowen Analyst forecast on CH:8EM
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/05/26
Analyst Phil Nadeau Reiterates Buy on Editas Medicine, Citing Promising EDIT-401 Data, Strong Cash Runway, and Large Untapped HeFH Opportunity
Chardan Capital Analyst forecast on CH:8EM
Geulah Livshits
Chardan Capital
Chardan Capital
CHF3.16
Buy
―
Reiterated
05/05/26
Editas Medicine price target raised to $4 from $3.50 at ChardanEditas Medicine price target raised to $4 from $3.50 at Chardan
RBC Capital Analyst forecast on CH:8EM
Luca Issi
RBC Capital
RBC Capital
CHF3.16
Hold
―
Reiterated
05/05/26
Editas Medicine (EDIT) Receives a Hold from RBC Capital
Truist Financial Analyst forecast on CH:8EM
Joon Lee
Truist Financial
Truist Financial
―
Hold
―
Reiterated
03/17/26
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), DocGo (NASDAQ: DCGO) and Editas Medicine (NASDAQ: EDIT)
J.P. Morgan Analyst forecast on CH:8EM
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Editas Medicine (NASDAQ: EDIT) and Ascend Wellness Holdings LLC (Other OTC: AAWH)
Wells Fargo Analyst forecast on CH:8EM
Yanan Zhu
Wells Fargo
Wells Fargo
CHF3.16
Hold
―
Reiterated
03/10/26
Wells Fargo Sticks to Its Hold Rating for Editas Medicine (EDIT)
Clear Street Analyst forecast on CH:8EM
William Maughan
Clear Street
Clear Street
CHF3.63
Buy
―
Reiterated
03/10/26
Clear Street Reaffirms Their Buy Rating on Editas Medicine (EDIT)
Barclays Analyst forecast on CH:8EM
Gena Wang
Barclays
Barclays
CHF2.37
Hold
―
Reiterated
11/11/25
Barclays Keeps Their Hold Rating on Editas Medicine (EDIT)
Robert W. Baird Analyst forecast on CH:8EM
Jack Allen
Robert W. Baird
Robert W. Baird
CHF3.16→CHF4.73
Buy
―
Reiterated
08/13/25
Editas Medicine price target raised to $6 from $4 at BairdEditas Medicine price target raised to $6 from $4 at Baird
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on CH:8EM
Jonathan Miller
Evercore ISI
Evercore ISI
CHF11.84
Buy
―
Reiterated
05/27/26
Editas Medicine preclinical data 'looks highly supportive,' says Evercore ISIEditas Medicine preclinical data 'looks highly supportive,' says Evercore ISI
H.C. Wainwright Analyst forecast on CH:8EM
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF3.95
Buy
―
Reiterated
05/26/26
Analyst Maintains Buy on Editas Medicine, Reiterates $5 Price Target on EDIT-401 Progress and Strong Cash Runway
JonesTrading Analyst forecast on CH:8EM
Boris Peaker
JonesTrading
JonesTrading
CHF10.26→CHF6.31
Buy
―
Reiterated
05/14/26
JonesTrading Keeps Their Buy Rating on Editas Medicine (EDIT)
Bank of America Securities Analyst forecast on CH:8EM
Alec Stranahan
Bank of America Securities
Bank of America Securities
―
Sell
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (NYSE: BKD), Tempus AI, Inc. Class A (NASDAQ: TEM) and Editas Medicine (NASDAQ: EDIT)
TD Cowen Analyst forecast on CH:8EM
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/05/26
Analyst Phil Nadeau Reiterates Buy on Editas Medicine, Citing Promising EDIT-401 Data, Strong Cash Runway, and Large Untapped HeFH Opportunity
Chardan Capital Analyst forecast on CH:8EM
Geulah Livshits
Chardan Capital
Chardan Capital
CHF3.16
Buy
―
Reiterated
05/05/26
Editas Medicine price target raised to $4 from $3.50 at ChardanEditas Medicine price target raised to $4 from $3.50 at Chardan
RBC Capital Analyst forecast on CH:8EM
Luca Issi
RBC Capital
RBC Capital
CHF3.16
Hold
―
Reiterated
05/05/26
Editas Medicine (EDIT) Receives a Hold from RBC Capital
Truist Financial Analyst forecast on CH:8EM
Joon Lee
Truist Financial
Truist Financial
―
Hold
―
Reiterated
03/17/26
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), DocGo (NASDAQ: DCGO) and Editas Medicine (NASDAQ: EDIT)
J.P. Morgan Analyst forecast on CH:8EM
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Editas Medicine (NASDAQ: EDIT) and Ascend Wellness Holdings LLC (Other OTC: AAWH)
Wells Fargo Analyst forecast on CH:8EM
Yanan Zhu
Wells Fargo
Wells Fargo
CHF3.16
Hold
―
Reiterated
03/10/26
Wells Fargo Sticks to Its Hold Rating for Editas Medicine (EDIT)
Clear Street Analyst forecast on CH:8EM
William Maughan
Clear Street
Clear Street
CHF3.63
Buy
―
Reiterated
03/10/26
Clear Street Reaffirms Their Buy Rating on Editas Medicine (EDIT)
Barclays Analyst forecast on CH:8EM
Gena Wang
Barclays
Barclays
CHF2.37
Hold
―
Reiterated
11/11/25
Barclays Keeps Their Hold Rating on Editas Medicine (EDIT)
Robert W. Baird Analyst forecast on CH:8EM
Jack Allen
Robert W. Baird
Robert W. Baird
CHF3.16→CHF4.73
Buy
―
Reiterated
08/13/25
Editas Medicine price target raised to $6 from $4 at BairdEditas Medicine price target raised to $6 from $4 at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Editas Medicine

3 Months
Phil NadeauTD Cowen
Success Rate
8/15 ratings generated profit
53%
Average Return
-0.96%
Copying Phil Nadeau's trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of -0.96% per trade.
1 Year
Phil NadeauTD Cowen
Success Rate
11/15 ratings generated profit
73%
Average Return
+23.71%
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +23.71% per trade.
2 Years
Phil NadeauTD Cowen
Success Rate
11/15 ratings generated profit
73%
Average Return
+42.41%
Copying Phil Nadeau's trades and holding each position for 2 Years would result in 73.33% of your transactions generating a profit, with an average return of +42.41% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

8EM Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
2
4
8
6
Buy
0
1
1
3
2
Hold
2
5
3
4
1
Sell
1
2
1
2
1
Strong Sell
0
0
0
0
0
total
3
10
9
17
10
In the current month, 8EM has received 8 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. 8EM average Analyst price target in the past 3 months is 5.03.
Each month's total comprises the sum of three months' worth of ratings.

8EM Financial Forecast

8EM Earnings Forecast

Next quarter’s earnings estimate for 8EM is -CHF0.21 with a range of -CHF0.25 to -CHF0.17. The previous quarter’s EPS was -CHF0.20. 8EM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 8EM has Performed in-line its overall industry.
Next quarter’s earnings estimate for 8EM is -CHF0.21 with a range of -CHF0.25 to -CHF0.17. The previous quarter’s EPS was -CHF0.20. 8EM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 8EM has Performed in-line its overall industry.

8EM Sales Forecast

Next quarter’s sales forecast for 8EM is CHF2.35M with a range of CHF391.71K to CHF6.17M. The previous quarter’s sales results were CHF2.22M. 8EM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 8EM has Performed in-line its overall industry.
Next quarter’s sales forecast for 8EM is CHF2.35M with a range of CHF391.71K to CHF6.17M. The previous quarter’s sales results were CHF2.22M. 8EM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 8EM has Performed in-line its overall industry.

8EM Stock Forecast FAQ

What is CH:8EM’s average 12-month price target, according to analysts?
Based on analyst ratings, Editas Medicine Inc’s 12-month average price target is 5.03.
    What is CH:8EM’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:8EM, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Editas Medicine Inc a Buy, Sell or Hold?
        Editas Medicine Inc has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 3 hold ratings and 2 sell ratings.
          What is Editas Medicine Inc’s share price target?
          The average share price target for Editas Medicine Inc is 5.03. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF11.84 ,and the lowest forecast is CHF3.16. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Editas Medicine Inc?
            Editas Medicine Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
              How can I buy shares of Editas Medicine Inc?
              To buy shares of CH:8EM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.